Atea Pharmaceuticals (AVIR) Total Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $267.1 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 824.78% year-over-year to $267.1 million; the TTM figure through Mar 2026 stood at $267.1 million (up 824.78% YoY), while the FY2025 annual figure was $39.8 million, up 54.2% from the prior year.
• Total Liabilities for Q1 2026 stood at $267.1 million, up from $39.8 million in the prior quarter.
• The five-year high for Total Liabilities was $267.1 million in Q1 2026, with the low at $19.9 million in Q1 2023.
• The 5-year median for Total Liabilities is $28.9 million (2025), against an average of $44.8 million.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities slumped 91.07% in 2022, then jumped 824.78% in 2026.
• Atea Pharmaceuticals' Total Liabilities stood at $26.1 million in 2022, then jumped by 52.19% to $39.8 million in 2023, then plunged by 35.13% to $25.8 million in 2024, then surged by 54.2% to $39.8 million in 2025, then soared by 571.32% to $267.1 million in 2026.
• Business Quant data shows AVIR's Total Liabilities at $267.1 million in Q1 2026, $39.8 million in Q4 2025, and $27.2 million in Q3 2025.